AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|
31.4 C
New York
Tuesday, June 30, 2026

Tag: patient

Hope Regional Cancer Center Earns Prestigious ACR Accreditation for Excellence in Cancer Care

PANAMA CITY, Fla., July 3, 2025 /PRNewswire/ -- Hope Regional Cancer Center is proud to announce that it has received its fourth consecutive full...

Dr. Louis Krenn Medical Scholarship: Empowering Future Leaders in Medicine

SPRINGFIELD, Mo., July 3, 2025 /PRNewswire/ -- The Dr. Louis Krenn Medical Scholarship is now accepting applications from aspiring medical professionals across the United...

Robotic Surgery Market 2025 Trends: Advanced AI Systems, Telesurgery and $400M Investments Power Global Expansion

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

$7.80 Billion by 2030: Why Single-Use Surgical Instruments Are Reshaping Global Surgery | MarketsandMarkets™

DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- What's fueling the shift from sterilization to scalability? The global single-use surgical instruments market, valued at US$5.60 billion...

Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as...

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

LEATHERHEAD, England, July 3, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark,...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient